What does longevity medicine actually do, and how do you separate evidence from hype?

What is aging actually, biologically?

Aging is increasingly understood as a set of identifiable cellular and molecular processes, often described as the "hallmarks of aging." These include:

• Genomic instability. Accumulating DNA damage over time
• Telomere shortening. The protective caps on chromosomes that shorten with each cell division
• Epigenetic alterations. Changes in how genes are expressed without changes to the underlying DNA
• Loss of proteostasis. Reduced ability to maintain proper protein structure and function
• Mitochondrial dysfunction. Declining function of the energy-producing structures inside cells
• Cellular senescence. Cells that have stopped dividing but remain metabolically active and inflammatory
• Stem cell exhaustion. Reduced capacity for tissue repair and regeneration
• Altered intercellular communication. Changes in how cells signal to each other
• Deregulated nutrient sensing. Changes in how cells respond to nutrients
• Microbiome changes. Shifts in the gut bacteria that affect metabolism and inflammation

Each hallmark is now a research target for interventions that may slow or reverse aspects of aging. Some have multiple interventions in clinical or preclinical development.

What interventions have the strongest evidence for longevity in humans?

The interventions with the most consistent evidence for extending healthspan and lifespan in humans:

• Regular exercise combining aerobic and resistance training. The most studied longevity intervention, with consistent evidence across cardiovascular, metabolic, cognitive, musculoskeletal, and mortality outcomes
• Adequate quality sleep, with appropriate architecture
• Nutrient-dense whole-food eating patterns. Mediterranean and traditional dietary patterns have the most consistent evidence
• Maintaining metabolic health. Insulin sensitivity, glucose stability, body composition
• Treating cardiovascular risk factors aggressively. Blood pressure, ApoB, Lp(a)
• Maintaining lean muscle and bone density through resistance training and adequate protein
• Strong social connections and continued cognitive engagement

These aren't novel. They're foundational. Most novel longevity interventions either build on these or attempt to substitute for them, and the substitutes generally don't work as well as the foundations.

What pharmaceuticals are most discussed in longevity medicine?

Several pharmaceuticals have meaningful longevity-related evidence:

• GLP-1 medications (semaglutide, tirzepatide). Originally diabetes drugs, now showing cardiovascular protection, possible cognitive benefits, and broader metabolic effects. The longevity implications are still being characterized but appear meaningful
• Metformin. Studied for longevity effects beyond diabetes management. The TAME (Targeting Aging with Metformin) trial is ongoing. Mechanism involves AMPK activation, modest mTOR inhibition (a cellular pathway involved in growth and aging), and improved insulin sensitivity. Most appropriate in patients with metabolic dysfunction
• Low-dose rapamycin. An mTOR inhibitor with the strongest animal evidence for lifespan extension of any compound. Human longevity outcomes remain unproven; trials are ongoing. Some clinicians use intermittent low-dose protocols off-label. Side effect profile is meaningful and clinical use remains experimental
• SGLT2 inhibitors. Cardiovascular and renal protective effects beyond glucose lowering, with potential broader applications

These represent the more evidence-based pharmaceutical layer of longevity medicine. They're tools, not magic.

What about NAD+, NMN, and similar supplements?

NAD+ (nicotinamide adenine dinucleotide) is essential for cellular energy production, DNA repair, and sirtuin activity (a class of proteins involved in aging regulation). NAD+ levels decline with age. NAD+ precursors (NMN, NR) raise NAD+ levels in humans, but human longevity outcomes remain unproven.

The state of evidence:

• Animal evidence: strong for various health and lifespan outcomes
• Human evidence: improvements in some specific contexts (cardiovascular markers, metabolic measures) but limited longevity outcome data
• Clinical use: widespread in longevity-focused practice, with the appropriate framing being "promising but unproven for longevity in humans"

The honest framing: NAD+ pathways are biologically important, NAD+ precursor supplementation raises NAD+ levels, and there's reason to think this matters for healthspan, but human longevity data is still emerging. People who take NMN or NR aren't doing something foolish; they're just doing something whose long-term benefits aren't yet definitively established.

What are senolytics?

Senolytics are interventions designed to selectively clear senescent cells. Senescent cells are cells that have stopped dividing but remain metabolically active, secreting inflammatory signals (called the senescence-associated secretory phenotype, or SASP) that damage surrounding tissue. They accumulate with age and contribute to many age-related conditions.

Compounds with senolytic activity include some pharmaceuticals (dasatinib, navitoclax) and some natural compounds (fisetin, quercetin in combination, certain flavonoids). The animal evidence is striking: clearing senescent cells in mice extends healthspan and reverses some age-related dysfunction.

Human evidence is still emerging. Several trials are underway. The mechanistic basis is strong, but human outcomes haven't yet been demonstrated at the same level as animal studies.

How does hormone optimization fit into longevity medicine?

Addressing hormonal decline can affect quality of life, body composition, cognitive function, bone density, and cardiovascular risk. Hormone therapy in perimenopausal and postmenopausal women is increasingly recognized as having longevity-relevant benefits when initiated within 10 years of menopause, particularly cardiovascular and bone protection. Testosterone optimization in symptomatic men with confirmed deficiency has metabolic and quality-of-life benefits, with cardiovascular safety better established than previously feared.

Hormone optimization doesn't extend lifespan dramatically in healthy people. Its primary value is preserving function during the years a person has, which is the healthspan question.

Why does muscle matter so much for longevity?

Skeletal muscle does more than enable movement. It's:

• The primary site of glucose disposal (so more muscle improves metabolic health)
• An endocrine tissue producing myokines that regulate inflammation and metabolism
• The largest reservoir of amino acids for immune function
• The functional foundation of physical independence

Sarcopenia (the age-related loss of muscle mass) is a stronger predictor of mortality and disability in older adults than body fat percentage [PMID: 25365952]. Without intervention, the average adult loses approximately 8% of muscle mass per decade up to age 70.

Resistance training and adequate protein intake (often 0.7 to 1.0 grams per pound of lean body mass for active adults) prevent and even reverse sarcopenia. This single domain has effects across all four healthspan domains.

What's the calibrated honesty about longevity medicine?

The field includes well-evidenced interventions and speculative ones, and honest framing matters:

• Strong evidence: Exercise, sleep, nutrition, metabolic health, cardiovascular risk reduction, hormone optimization where indicated
• Moderate evidence: GLP-1 medications, metformin in metabolically dysfunctional patients, certain peptides, some specific nutrients
• Limited human evidence (animal-supported): NAD+ precursors, most senolytics, low-dose rapamycin, urolithin A, many novel compounds

A lot of what's marketed in the longevity space gets ahead of the evidence. Calibrated, evidence-aware longevity care is what distinguishes clinical practice from supplement marketing.

The deeper picture

Longevity medicine sits at the intersection of well-established preventive medicine and emerging science. Working with a physician who tracks the evidence as it develops, distinguishes what's actually proven from what's still speculative, and builds individualized plans based on each patient's risk profile and goals is what makes this field clinical rather than commercial. Extend approaches longevity care this way.